PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 61 filers reported holding PRELUDE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 6.00 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $12,961,196 | 0.0% | 2,273,894 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $12,961,196 | -8.1% | 2,273,894 | -2.7% | 0.01% | -14.3% |
| Q4 2022 | $14,109,102 | -99.9% | 2,335,944 | -2.8% | 0.01% | -22.2% |
| Q3 2022 | $15,881,153,000 | +25.7% | 2,402,595 | -0.7% | 0.01% | +28.6% |
| Q2 2022 | $12,635,151,000 | -24.4% | 2,420,527 | -0.1% | 0.01% | 0.0% |
| Q1 2022 | $16,714,056,000 | -11.3% | 2,422,327 | +60.0% | 0.01% | 0.0% |
| Q4 2021 | $18,845,391,000 | -59.3% | 1,513,686 | +2.0% | 0.01% | -63.2% |
| Q3 2021 | $46,353,719,000 | +25.7% | 1,483,319 | +15.2% | 0.02% | +18.8% |
| Q2 2021 | $36,867,853,000 | +32.3% | 1,287,735 | +100.3% | 0.02% | +33.3% |
| Q1 2021 | $27,860,280,000 | -24.5% | 642,979 | +24.6% | 0.01% | -29.4% |
| Q4 2020 | $36,921,875,000 | +68.7% | 516,029 | -29.0% | 0.02% | +41.7% |
| Q3 2020 | $21,888,330,000 | – | 726,463 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $313,740,000 | 3.45% |
| Baker Brothers Advisors | 10,123,824 | $316,370,000 | 1.39% |
| Logos Global Management LP | 400,000 | $12,500,000 | 0.90% |
| HHLR ADVISORS, LTD. | 583,333 | $18,229,000 | 0.24% |
| Rock Springs Capital Management LP | 362,359 | $11,324,000 | 0.24% |
| Virtus ETF Advisers LLC | 6,292 | $197,000 | 0.09% |
| FEDERATED HERMES, INC. | 408,100 | $12,753,000 | 0.02% |
| Virtu Financial LLC | 7,940 | $248,000 | 0.02% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 1,483,319 | $46,353,719,000 | 0.02% |
| FMR LLC | 7,055,666 | $220,489,000 | 0.02% |